Gout and hyperuricemia are often treated with urate-lowering therapy (ULT) such as xanthine oxidase inhibitors, uricosuric drugs, uricolytic enzymes, losartan, and sodium-glucose cotransporter-2 inhibitors (Dalbeth, Merriman & Stamp, 2016; FitzGerald et al., 2020; Richette et al., 2017), although the recent guidelines advise against the routine treatment of asymptomatic hyperuricemia in the absence of related symptoms or conditions (FitzGerald et al., 2020). Here, SLC5A2 is linked to hyperuricemia.